Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Inspire reports success in pollen allergy drug study
The phase II clinical trial was a 14-day, randomized, double-blind comparison of two doses of epinastine nasal spray (0.05% and 0.1%) to placebo in 569 subjects who had
The phase II clinical trial was a 14-day, randomized, double-blind comparison of two doses of epinastine nasal spray (0.05% and 0.1%) to placebo in 569 subjects who had
The study evaluated two concentrations of bepotastine, each dosed once daily and twice daily. The primary endpoints of the study were the assessment of efficacy for bepotastine in
The initial phase II study will test single and repeated doses of BIIB014 in patients with late-stage Parkinson’s disease, in addition to the usual L-dopa therapy. The second
The drug is a bioreductively-activated, hypoxia-selective small molecule that acts primarily in hypoxic regions of tumors, wherein tirapazamine radicals cause double-stranded DNA breaks. It was originally identified as
A compulsory license allows Brazil, under World Trade Organization (WTO) rules, to buy or manufacture generic versions of the drug. Thailand recently earned itself a place on the
Specifically, Abbott has applied to market Humira (adalimumab) as a treatment for juvenile rheumatoid arthritis (JRA) in the US and juvenile idiopathic arthritis (JIA) in the European Union.
Alba’s study, the first phase IIa trial in celiac disease (CD) and the first to assess dosing requirements for AT-1001 in CD, was designed to evaluate the safety,
The patient died from fulminant hepatitis, also known as acute liver failure, according to the company. Astellas is jointly developing the compound with US biotech company FibroGen, which
New data from a randomized, double-blind study showed that a combination of Copaxone with the oral antibiotic minocycline reduced T1 Gadolinium enhancing lesions of the brain by 63%
The drug discovery programs currently being managed in Waltham will be moved to Munich, where the company has its headquarters, while GPC will continue to build its clinical